再生元制药集团(Regeneron Pharmaceuticals Inc)今天盘中大涨5.02%,表现强劲。该公司公布了2024年第四季度财报,业绩超出市场预期,令投资者增加看多信心。
财报显示,再生元制药集团第四季度调整后每股收益为12.07美元,高于分析师平均预期的11.28美元。营业收入为37.9亿美元,也超出了37.5亿美元的预期。其抗炎症药物Dupixent的销售额达到37亿美元,同比增长15%,贡献了公司业绩的大幅增长。
令投资者更加看好的是,再生元制药集团还宣布了一项每股88美分的现金分红计划,以及新增30亿美元的股票回购计划。这体现了公司对未来现金流的信心,利好股价表现。综合以上原因,分析师对该股长期增长前景看好,推动股价今天大涨5.02%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.